Free Trial

Telomir Pharmaceuticals (TELO) Competitors

Telomir Pharmaceuticals logo
$1.57 -0.05 (-3.09%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$1.58 +0.01 (+0.64%)
As of 10/17/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TELO vs. IPHA, MIST, FBRX, CRBP, ANRO, SAVA, GNLX, ELDN, IVVD, and ACTU

Should you be buying Telomir Pharmaceuticals stock or one of its competitors? The main competitors of Telomir Pharmaceuticals include Innate Pharma (IPHA), Milestone Pharmaceuticals (MIST), Forte Biosciences (FBRX), Corbus Pharmaceuticals (CRBP), Alto Neuroscience (ANRO), Cassava Sciences (SAVA), Genelux (GNLX), Eledon Pharmaceuticals (ELDN), Invivyd (IVVD), and Actuate Therapeutics (ACTU). These companies are all part of the "pharmaceutical products" industry.

Telomir Pharmaceuticals vs. Its Competitors

Innate Pharma (NASDAQ:IPHA) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Innate Pharma has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500. Comparatively, Telomir Pharmaceuticals has a beta of -0.6, meaning that its stock price is 160% less volatile than the S&P 500.

Innate Pharma presently has a consensus target price of $6.50, suggesting a potential upside of 200.23%. Telomir Pharmaceuticals has a consensus target price of $15.00, suggesting a potential upside of 855.41%. Given Telomir Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Telomir Pharmaceuticals is more favorable than Innate Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Innate Pharma
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Telomir Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67

Telomir Pharmaceuticals has lower revenue, but higher earnings than Innate Pharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Innate Pharma$21.77M9.17-$53.53MN/AN/A
Telomir PharmaceuticalsN/AN/A-$16.53M-$0.54-2.91

0.2% of Innate Pharma shares are held by institutional investors. 31.9% of Innate Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Innate Pharma's return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Innate PharmaN/A N/A N/A
Telomir Pharmaceuticals N/A -4,595.08%-1,750.91%

In the previous week, Telomir Pharmaceuticals had 2 more articles in the media than Innate Pharma. MarketBeat recorded 3 mentions for Telomir Pharmaceuticals and 1 mentions for Innate Pharma. Telomir Pharmaceuticals' average media sentiment score of 0.03 beat Innate Pharma's score of 0.00 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Innate Pharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Telomir Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Innate Pharma and Telomir Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

Get Telomir Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TELO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TELO vs. The Competition

MetricTelomir PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$50.68M$2.97B$6.19B$10.55B
Dividend YieldN/A54.20%5.70%4.81%
P/E Ratio-2.9122.9985.5427.13
Price / SalesN/A765.78611.78133.04
Price / CashN/A169.4137.1060.81
Price / Book78.505.3212.236.52
Net Income-$16.53M$33.06M$3.33B$276.93M
7 Day Performance-4.85%2.29%1.17%1.93%
1 Month Performance2.61%7.35%6.85%2.19%
1 Year Performance-66.60%-5.13%58.93%34.62%

Telomir Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TELO
Telomir Pharmaceuticals
2.8557 of 5 stars
$1.57
-3.1%
$15.00
+855.4%
-66.6%$50.68MN/A-2.911Short Interest ↓
Gap Down
IPHA
Innate Pharma
2.0856 of 5 stars
$1.96
-0.8%
$6.50
+231.6%
+9.3%$182.12M$21.77M0.00220
MIST
Milestone Pharmaceuticals
2.1545 of 5 stars
$2.08
-1.9%
$4.50
+116.3%
+30.2%$180.19M$1M-2.4830
FBRX
Forte Biosciences
2.7809 of 5 stars
$14.23
-1.4%
$68.00
+377.9%
+157.6%$179.41MN/A-0.875News Coverage
Analyst Downgrade
Options Volume
CRBP
Corbus Pharmaceuticals
3.9477 of 5 stars
$14.61
+0.6%
$45.43
+210.9%
+4.9%$177.95MN/A-3.0740
ANRO
Alto Neuroscience
1.9334 of 5 stars
$5.96
-8.9%
$9.80
+64.4%
-57.8%$177.08MN/A-2.49N/A
SAVA
Cassava Sciences
2.4851 of 5 stars
$3.42
-4.2%
$2.00
-41.5%
-85.2%$172.46MN/A-1.3430
GNLX
Genelux
0.8306 of 5 stars
$4.71
+3.7%
$20.33
+331.7%
+108.0%$171.49M$10K-5.4810
ELDN
Eledon Pharmaceuticals
1.8091 of 5 stars
$2.73
-4.5%
$10.00
+266.3%
+15.8%$171.26MN/A-2.3310News Coverage
Gap Up
IVVD
Invivyd
3.8523 of 5 stars
$1.63
+14.8%
$5.14
+215.2%
+80.0%$170.60M$25.38M-1.77100Analyst Downgrade
High Trading Volume
ACTU
Actuate Therapeutics
1.444 of 5 stars
$7.04
+0.3%
$20.33
+188.8%
+3.0%$163.17MN/A0.0010

Related Companies and Tools


This page (NASDAQ:TELO) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners